ERA 223: A phase 3 trial of radium-223 dichloride in combination with abiraterone acetate and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-na ve patients with bone-predominant metastatic castration-resistant prostate cancer.

被引：3
|
作者：
Smith, Matthew R.
Parker, Chris C.
Tombal, Bertrand F.
Miller, Kurt
Saad, Fred
Shen, Junwu
Zhang, Amily
Kornacker, Martin
Higano, Celestia S.
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[3] Inst Canc Res, Sutton, Surrey, England
[4] St Luc Univ Hosp, Brussels, Belgium
[5] Charite, Berlin, Germany
[6] Univ Montreal, Ctr Hosp, Montreal, PQ, Canada
[7] Bayer, Div Pharmaceut, Whippany, NJ USA
[8] Bayer Pharma AG, Berlin, Germany
[9] Univ Washington, Seattle, WA 98195 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS5088
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS5088
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Era 223-A Phase 3 Trial of Radium-223 Dichloride (Ra-223) in Combination with Abiraterone Acetate (Aa) and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapynaive patients with bone-predominant metastatic Castration Resistant Prostate Cancer (Crpc)
    Bracarda, S.
    Procopio, G.
    Parker, C.
    Tombal, B.
    Miller, K.
    Saad, F.
    Fang, F.
    Zhang, A.
    Kornacker, M.
    Higano, C.
    Smith, M. R.
    ANNALS OF ONCOLOGY, 2015, 26 : 57 - 57
  • [2] ERA 223: A phase 3 trial of radium-223 dichloride (Ra-223) in combination with abiraterone acetate (abiraterone) and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naive patients (pts) with bone predominant metastatic castration-resistant prostate cancer (mCRPC).
    Smith, Matthew Raymond
    Parker, Chris
    Tombal, Bertrand F.
    Miller, Kurt
    Saad, Fred
    Fang, Fang
    Zhang, Amily
    Kornacker, Martin
    Higano, Celestia S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naive patients (pts) with bone-predominant metastatic castration-resistant prostate cancer (mCRPC)
    Smith, M. R.
    Parker, C. C.
    Saad, F.
    Miller, K.
    Tombal, B.
    Ng, Q. S.
    Boegemann, M.
    Matveev, V.
    Piulats, J. M.
    Zucca, L. E.
    Heidenreich, A.
    Kakehi, Y.
    Zhang, A.
    Krissel, H.
    Shen, J.
    Wagner, V.
    Higano, C.
    ANNALS OF ONCOLOGY, 2018, 29
  • [4] Radium-223 Is the Preferred Therapy in Bone-Predominant Symptomatic Metastatic Castration-Resistant Prostate Cancer
    Dreicer, Robert
    Li, Jing
    Andrew, J.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (05) : 293 - +
  • [5] Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases
    Vogelzang, Nicholas J.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (08) : 809 - 819
  • [6] A phase IIa study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)
    Petrylak, D. P.
    Vaishampayan, U. N.
    Patel, K. R.
    Higano, C. S.
    Albany, C.
    Dawson, N. A.
    Mehlhaff, B. A.
    Quinn, D. I.
    Nordquist, L. T.
    Wagner, V. J.
    Shen, J.
    Trandafir, L.
    Sartor, O.
    ANNALS OF ONCOLOGY, 2019, 30 : 340 - 341
  • [7] eRADicAte: A Prospective Evaluation Combining Radium-223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients With Castration-Resistant Prostate Cancer
    Shore, Neal D.
    Tutrone, Ronald F.
    Mariados, Neil F.
    Nordquist, Luke T.
    Mehlhaff, Bryan A.
    Steere, Karyn J.
    Harrelson, Stacey S.
    CLINICAL GENITOURINARY CANCER, 2018, 16 (02) : 149 - 154
  • [8] Radium-223 Dichloride: A Novel Treatment Option for Castration-Resistant Prostate Cancer Patients With Symptomatic Bone Metastases
    McGann, Shane
    Horton, Evan R.
    ANNALS OF PHARMACOTHERAPY, 2015, 49 (04) : 469 - 476
  • [9] Evaluation of Radium-223 Dichloride in the Treatment of Castration-Resistant Prostate Adenocarcinoma with Symptomatic Bone Metastases
    Maestre-Cutillas, R.
    Sanchez-Tornero, A. M.
    Baz-Sanz, L.
    Rubio-Fernandez, G.
    Casas-Fernandez, L.
    Romero-Otero, M.
    Perez-Iruela, J. A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S652 - S652
  • [10] Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety
    Nilsson, Sten
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (07) : 1127 - 1136
12345